Impact of Elexacaftor/Tezacaftor/Ivacaftor Therapy on the Cystic Fibrosis Airway Microbial Metagenome
ABSTRACT The introduction of mutation-specific combination therapy with the cystic fibrosis transmembrane conductance regulator (CFTR) modulators elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) has substantially improved lung function and quality of life of people with cystic fibrosis (CF). Collectin...
Main Authors: | Sophia T. Pallenberg, Marie-Madlen Pust, Ilona Rosenboom, Gesine Hansen, Lutz Wiehlmann, Anna-Maria Dittrich, Burkhard Tümmler |
---|---|
Format: | Article |
Language: | English |
Published: |
American Society for Microbiology
2022-10-01
|
Series: | Microbiology Spectrum |
Subjects: | |
Online Access: | https://journals.asm.org/doi/10.1128/spectrum.01454-22 |
Similar Items
-
Case Report: When cystic fibrosis, elexacaftor/tezacaftor/ivacaftor therapy, and alpha1 antitrypsin deficiency get together
by: Rachel Kinuani, et al.
Published: (2024-04-01) -
Early and sustained improvements of lung clearance index from two to sixteen weeks of elexacaftor/tezacaftor/ivacaftor therapy in patients with cystic fibrosis—a real world study
by: Dorothea Appelt, et al.
Published: (2023-03-01) -
Post-approval studies with the CFTR modulators Elexacaftor-Tezacaftor—Ivacaftor
by: Burkhard Tümmler, et al.
Published: (2023-03-01) -
Changes in cystic fibrosis transmembrane conductance regulator protein expression prior to and during elexacaftor-tezacaftor-ivacaftor therapy
by: Frauke Stanke, et al.
Published: (2023-01-01) -
Elexacaftor/Tezacaftor/Ivacaftor Accelerates Wound Repair in Cystic Fibrosis Airway Epithelium
by: Onofrio Laselva, et al.
Published: (2022-09-01)